Agenus Inc.

Agenus Inc. ( AGEN ) Discusses BOT BAL Development and Planned Phase 3 ROBBIN Trial November 5, 2026 11:30 AM EST Company Participants Zack Armen - Vice President of Investor Relations & Corporate Development Robin Taylor - Chief Commercial Officer Conference Call Participants Michael King - Rodman & Renshaw Research Presentation Michael King Rodman & Renshaw Research All right. It looks like we've got the whole crowd here, so we're going to kick this off.

AGEN's Q3 earnings meet estimates, but a revenue miss weighs on shares as pipeline progress, Armenian drug approvals and new funding emerge as key developments.

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Botensilimab--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced new findings from a long-term survivor analysis of its Phase 1b C-800-01 trial evaluating botensilimab (BOT), a multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, in heavily pretreated patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases. The results were prese.

Agenus NASDAQ: AGEN expects to begin enrolling patients in the next few months for a Phase 3 trial of its investigational immunotherapy combination BOT/BAL in early-stage colon cancer, executives said during an investor event.